EP0669324A1 — Quinazoline compound
Assigned to Eisai Co Ltd · Expires 1995-08-30 · 31y expired
What this patent protects
A quinazoline compound represented by general formula (I), which is useful as a medicine having the activity as a calmodulin-dependent cGMP-PDE inhibitor, or a pharmacologically acceptable salt thereof wherein R 1 , R 2 , R 3 , R 4 and R 5 represent each independently hydrogen,…
USPTO Abstract
A quinazoline compound represented by general formula (I), which is useful as a medicine having the activity as a calmodulin-dependent cGMP-PDE inhibitor, or a pharmacologically acceptable salt thereof wherein R 1 , R 2 , R 3 , R 4 and R 5 represent each independently hydrogen, lower alkyl, etc.; and R 6 ad R 7 represent each independently hydrogen, carboxyalkyl, etc.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.